David R. Matthews

David R. Matthews

Auto-generated profile, based on publicly available information

David R. Matthews

Oxford Centre for Diabetes, Endocrinology and Metabolism Churchill Hospital Oxford UK

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2012 in Diabetologia
Verified
Journal Article
Open access
PDF file
SIS. E. Inzucchi
S. E. Inzucchi
RBR. M. Bergenstal
R. M. Bergenstal
JBJ. B. Buse
J. B. Buse
MDM. Diamant
M. Diamant
EFE. Ferrannini
E. Ferrannini
DMD. R. Matthews
D. R. Matthews

13 January 2015 in Diabetologia
Verified
Journal Article
Closed access
PDF file
SISilvio E. Inzucchi
Silvio E. Inzucchi
RBRichard M. Bergenstal
Richard M. Bergenstal
JBJohn B. Buse
John B. Buse
MDMichaela Diamant
Michaela Diamant
EFEle Ferrannini
Ele Ferrannini
DMDavid R. Matthews
David R. Matthews

28 June 2002 in Diabetic Medicine
Verified
Journal Article
Closed access
PDF file
TWT. M. Wallace
T. M. Wallace
DMD. R. Matthews
D. R. Matthews

1 November 2004 in Archives of Ophthalmology (1950)
Verified
Journal Article
Closed access
PDF file
DMDavid R Matthews
David R Matthews
ISIrene M Stratton
Irene M Stratton
SAStephen J Aldington
Stephen J Aldington
RHRury R Holman
Rury R Holman
EKEva M Kohner
Eva M Kohner
UGUK Prospective Diabetes Study Group
UK Prospective Diabetes Study Group
Research from JAMA Ophthalmology — Risks of Progression of Retinopathy and Vision Loss Related to TightBlood Pressure Control in Type 2 Diabetes Mellitus — UKPDS 69

18 August 2020 in Annals of Internal Medicine
Verified
Journal Article
Closed access
ATApostolos Tsapas
Apostolos Tsapas
IAIoannis Avgerinos
Ioannis Avgerinos
TKThomas Karagiannis
Thomas Karagiannis
KMKonstantinos Malandris
Konstantinos Malandris
AMApostolos Manolopoulos
Apostolos Manolopoulos
EBEleni Bekiari
Eleni Bekiari
This network meta-analysis involving 453 trials compares the benefits and harms of 21 antidiabetic interventions from 9 drug classes for adults with type 2 diabetes. Efficacy of the regimens appear... Background: Several pharmacologic options for type 2 diabetes are available. Purpose: To compare benefits and harms of glucose-lowering drugs in adults with type 2 diabetes. Data Sources: Several d...

1 October 2019 in The Lancet
Verified
Journal Article
Closed access
DMDavid R Matthews
David R Matthews
PPPäivi M Paldánius
Päivi M Paldánius
PPPieter Proot
Pieter Proot
YCYannTong Chiang
YannTong Chiang
MSMichael Stumvoll
Michael Stumvoll
SPStefano Del Prato
Stefano Del Prato